It is a great pleasure and privilege to invite you again to the traditional ART Vienna conference on advanced retinal therapy in the year of 2021. There is no doubt that innovation has continued it’s dynamic force supported by advanced technology leading to a substantial increase in knowledge, particularly in retina. Exchange of insight and expertise, clinical and scientific results and active initiatives are vital for bringing “codes to clinic” and quality to patients.
Our team has put together three major sessions with the topics AMD, AI and retinal surgery and invited speakers that have excelled in moving the field towards new horizons.
For a lively exchange of ideas and a robust understanding of contents, face-to-face encounters are essential. As COVID-regulations are fully implemented, this year’s conference can provide this most important inter-individual exchange again. Interactive discussion and debate, missed for so long, will be even strengthened by having panel discussions with participation of all speakers in small groups related to their comment topic.
Kindly use the link to our home page under www.artvienna.eu
With this spirit of moving the field of retina ahead in a collaborative and person-driven effort, we are very much looking forward to see and hear you on December 3rd, 2022.
Univ.-Prof. Dr. Ursula Schmidt-Erfurth
Professor and Chair
Medical University Vienna
Department of Ophthalmology and Optometry
Austrian Academy of Sciences
08:15 WELCOME AND OPENING
08:30 SESSION 1: Brave new world: Novel substances and novel insights
- 08:30-08:40 | Karl G. Czaky, USA :The IRIS registry conclusions of efficacy of nAMD management
- 08:40-08:50 | Catherine Creuzot-Garcher, FR: The real-world in Europe: FRB outcomes in neovascular AMD
- 08:50-09:00 | Nancy Holecamp, USA: Better Eylea with higher dose
- 09:00-09:10 | Tariq Aslam, UK: Shared-care and telemedicine in nAMD management
- 09:10-09:20 | Tiarnan Keenan, USA : A consensus report on the management of fluid in nAMD
- 09:20-09:30 | Barbara Blodi, USA: Ultrawidefield Fluorescein Angiography in Retinal Vein Occlusion: 5 Year Data from SCORE2 Trial
09:30-09:50 | PANEL DISCUSSION
09:50-10:20 | COFFEE BREAK
10:20-11:20 SESSION 2: Artificial Intelligence
- 10:20-10:30 | Amitha Domalpally, USA: Evaluation of disease activity in nAMD: How good or bad is human expert judgement?
- 10:30-10:40 | Nancy Holekamp, USA: The Home-OCT: Impact of AI on nAMD management
- 10:40-10:50 | Eric Michael Moult, USA: OCT/OCTA biomarkers of local GA growth rate
- 10:50-11:00 | Ursula Schmidt-Erfurth, AT: The fluid monitor in clinical routine
- 11:00-11:10 | Lisa Koch, GER: Explainable AI in ophthalmology
- 11:10-11:20 | Nikolas Pontikos, UK: AI-based decision support systems for rare retinal diseases
11:20-11:40 | PANEL DISCUSSION
11:40-12:45 | LUNCH BREAK
12:45-13:30: SESSION 3 : Diabetes
- 12:45-13:00 | Daniel Barthelmes, CH: Long-term real-world treatment of DME – Experience from the FRB! Registry
- 13:00-13:15 | Riccardo Sacconi , IT: “Chicken-and-egg” - Neurodegeneration vs. microvasculopathy as earliest signs of DR - Does imaging have the answer?
- 13:25-13:30 | Tilman Schmoll , AT: Deciphering the retinal periphery in diabetic patients using OCT technology – Venturing into new realms
13:30-13:45 | PANEL DISCUSSION
13:45-14:15 | COFFEE BREAK
14:15-15:15 SESSION 4: Geographic Atrophy
- 14:15-14:25 | Thomas Ach, GER: The Role of RPE und HRF in GA
- 14:25-14:35 | Andreas Pollreisz, AT: How does the RPE age
- 14:35-14:45 | Tariq M Aslam, UK: Translating the Machine: Use of AI in non-nAMD
- 14:45-14:55 | Karl G Csaky, USA: Functional testing and restoring vision using gene therapy in GA
- 14:55-15:05 | Tiarnan Keenan, USA: Progression of GA in the AREDS population
- 15:05-15:15 | Gregor Reiter, Austria: Dynamics of GA lesion growth from early to advanced disease
15:15-15:35 | PANEL DISCUSSION